Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.950
+0.080 (2.79%)
At close: Jul 20, 2026, 4:00 PM EDT
2.910
-0.040 (-1.36%)
After-hours: Jul 20, 2026, 7:34 PM EDT
Lantern Pharma Employees
Lantern Pharma had 16 employees as of December 31, 2025. The number of employees decreased by 8 or -33.33% compared to the previous year.
Employees
16
Change (1Y)
-8
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$994,489
Market Cap
37.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -8 | -33.33% | 16 | 0 |
| Dec 31, 2024 | 24 | 3 | 14.29% | 24 | 0 |
| Dec 31, 2023 | 21 | -2 | -8.70% | 21 | 0 |
| Dec 31, 2022 | 23 | 7 | 43.75% | 22 | 1 |
| Dec 31, 2021 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
| Apollomics | 14 |
| Nutriband | 13 |
| Actuate Therapeutics | 12 |
| Genenta Science | 9 |
| NanoViricides | 7 |
LTRN News
- 12 days ago - Lantern Pharma launches ZetaOmics computational-biology module - TheFly
- 12 days ago - Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer - Business Wire
- 19 days ago - Lantern Pharma Slides: Corporate presentation - Filings
- 5 weeks ago - Lantern Pharma files to sell 2.24M shares of common stock for holders - TheFly
- 5 weeks ago - Lantern Pharma Registration statement: Registration filing - Filings
- 6 weeks ago - Lantern Pharma reports data, updates from Phase 2 Harmonic trial on LP-300 - TheFly
- 6 weeks ago - Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - Business Wire
- 2 months ago - Lantern receives successful response to Type C meeting from FDA on LP-300 - TheFly